Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
The narrow version of the question is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
Numbers rather than impressions, if you have them.
Dr.ReproEndo said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 115 | 101 | 91 | 85 |
| Insulin (fasting) | 21 | 15 | 11 | 5 |
| HOMA-IR | 5.5 | 3.1 | 1.9 | 1.4 |
| Uric Acid | 7.8 | 6.5 | 5.8 | 5.1 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.
DebRD_ATL said:Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:
HOMA-IR = (fasting insulin × fasting glucose) ÷ 405
My numbers: Baseline HOMA-IR = 6.1 (insulin resistant) → Current = 1.5 (insulin sensitive)
Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.ReproEndo said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Adding a me-too, because a thread of one person's experience is not much use.
Adding the clinical framing, because it changes how the question reads.
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 22%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.